# A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity

> **NCT06226090** · PHASE2 · COMPLETED · sponsor: **CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.** · enrollment: 314 (actual)

## Conditions studied

- Obesity
- Overweight

## Interventions

- **DRUG:** TG103 7.5 mg
- **DRUG:** Placebo 7.5 mg
- **DRUG:** TG103 15 mg
- **DRUG:** Placebo 15 mg
- **DRUG:** TG103 22.5 mg
- **DRUG:** Placebo 22.5 mg

## Key facts

- **NCT ID:** NCT06226090
- **Lead sponsor:** CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-02-21
- **Primary completion:** 2024-09-26
- **Final completion:** 2024-10-24
- **Target enrollment:** 314 (ACTUAL)
- **Last updated:** 2025-05-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06226090

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06226090, "A Study of TG103 Injection in the Management of Non-diabetic Overweight or Obesity". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06226090. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*